Celecoxib-d7

Celecoxib-d₇ is intended for use as an internal standard for the quantification of celecoxib by GC- or LC-MS. Celecoxib is a selective inhibitor of COX-2 (IC₅₀s = 22.9 and 0.05 μM for COX-1 and COX-2, respectively).^1,2 It displays chemopreventive activity in multiple tumor types via proapoptotic effects that are independent of COX-2 inhibition.^3,4,5 Formulations containing celecoxib have been used in the treatment of inflammation while circumventing the gastrointestinal toxicity associated with traditional non-sterodial anti-inflammatory drugs, however, the use of celecoxib has been tempered due to its ability to induce adverse cardiovascular events.⁶

1.Uddin, J.M., Rao, P.N.P., and Knaus, E.E.Design and synthesis of novel celecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: Replacement of the sulfonamide pharmacophore by a sulfonylazide bioisostereBioorg. Med. Chem.11(23)5273-5280(2003) 2.Mardini, I.A., and Fitzgerald, G.A.Selective inhibitors of cyclooxygenase-2: A growing class of anti-inflammatory drugsMolecular Interventions1(1)30-38(2001) 3.Jendrossek, V., Handrick, R., and Belka, C.Celecoxib activates a novel mitochondrial apoptosis signaling pathwayThe FASEB Journal171547-1549(2003) 4.Leahy, K.M., Ornberg, R.L., Wang, Y., et al.Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivoCancer Research62625-631(2002) 5.Zhu, J., Huang, J.W., Tseng, P.H., et al.From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitorsCancer Res.644309-4318(2004) 6.Blobaum, A.L., and Marnett, L.J.Structural and functional basis of cyclooxygenase inhibitionJ. Med. Chem.50(7)1425-1441(2007)